20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Corvus Pharmaceuticals, Inc. - (CRVS) operates in the NASDAQ industry and is headquartered in South San Francisco, United States with about 37 employees. Its market capitalization is roughly $1 billion. In the fiscal year ended 2025-12-31, CRVS reported $0M in revenue and ($15M) in net income.
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States.
Interactive charts & full statements →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | — | $0M | $0M | $0M | $0M | $0M | ($1M) | ($1M) | ($1M) | ($1M) | ($1M) | $0M | $0M |
| Gross Margin % | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Income (EBIT) | ($57M) | ($43M) | ($28M) | ($23M) | ($33M) | ($39M) | ($44M) | ($49M) | ($49M) | ($57M) | ($37M) | ($14M) | $0M |
| Operating Margin % | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Income | ($54M) | ($15M) | ($62M) | ($27M) | ($41M) | ($43M) | ($5M) | ($44M) | ($47M) | ($56M) | ($36M) | ($31M) | $0M |
| Net Margin % | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EBITDA | ($51M) | ($15M) | ($62M) | ($27M) | ($41M) | ($43M) | ($43M) | ($48M) | ($48M) | ($56M) | ($36M) | ($31M) | $0M |
| Earnings Per Share (EPS) | $-0.62 | $-0.19 | $-1.02 | $-0.56 | $-0.89 | $-1.03 | $-0.16 | $-1.49 | $-1.71 | $-2.72 | $-2.36 | $-1.54 | $-1.03 |
| Shares Outstanding (M) | 92M | 80M | 61M | 48M | 47M | 42M | 29M | 29M | 28M | 20M | 15M | 20M | 0M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | — | $0M | $0M | — | $0M | $0M | $0M | $0M |
| Gross Margin % | — | — | — | — | — | — | 50.0% | — |
| Operating Income (EBIT) | ($19M) | ($15M) | ($12M) | ($11M) | ($10M) | ($10M) | ($8M) | ($7M) |
| Operating Margin % | — | — | — | — | — | — | -9210.2% | — |
| Net Income | ($18M) | ($14M) | ($12M) | ($10M) | ($8M) | $15M | ($12M) | ($40M) |
| Net Margin % | — | — | — | — | — | — | -13764.8% | — |
| EBITDA | ($17M) | ($12M) | ($12M) | ($10M) | ($8M) | $15M | ($12M) | ($40M) |
| Earnings Per Share (EPS) | $-0.19 | $-0.15 | $-0.15 | $-0.12 | $-0.10 | $0.20 | $-0.18 | $-0.60 |
| Shares Outstanding (M) | 92M | 90M | 80M | 83M | 78M | 75M | 68M | 67M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($45M) | ($33M) | ($25M) | ($24M) | ($27M) | ($37M) | ($35M) | ($37M) | ($41M) | ($46M) | ($28M) | ($11M) | $0M |
| Capital Expenditures (CapEx) | $1M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $2M | $2M | $2M |
| Free Cash Flow (FCF) | ($45M) | ($33M) | ($25M) | ($24M) | ($27M) | ($37M) | ($35M) | ($37M) | ($41M) | ($46M) | ($30M) | ($13M) | ($2M) |
| FCF Margin % | — | — | — | — | — | — | — | — | — | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($15M) | ($10M) | ($9M) | ($10M) | ($6M) | ($8M) | ($8M) | ($6M) |
| Capital Expenditures (CapEx) | $1M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($16M) | ($10M) | ($9M) | ($10M) | ($6M) | ($8M) | ($8M) | ($6M) |
| FCF Margin % | — | — | — | — | — | — | -9619.3% | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $239M | $71M | $69M | $46M | $68M | $109M | $86M | $84M | $118M | $95M | $140M | $98M | $13M |
| Cash & Cash Equivalents | $19M | $5M | $9M | $13M | $13M | $63M | $16M | $5M | $115M | $90M | $135M | $4M | $13M |
| Total Liabilities | $14M | $10M | $36M | $7M | $12M | $12M | $13M | $13M | $8M | $10M | $7M | $130M | $13M |
| Total Debt (Short + Long-Term) | $0M | $0M | $0M | $1M | $1M | $1M | $1M | $1M | $0M | $0M | $0M | $0M | $3M |
| Total Shareholders' Equity | $225M | $61M | $33M | $39M | $56M | $97M | $72M | $71M | $110M | $85M | $133M | ($31M) | $0M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive CRVS viewer.
About TickerBase · Data methodology & sources · Privacy · Terms